Medical-device maker Medtronic in talks to buy Irish rival

June 15, 2014

US medical-device maker Medtronic is in advanced talks to buy competitor Covidien, based in Ireland, for more than $40 billion, The Wall Street Journal reported Saturday.

The deal, which could be announced Monday, would allow Medtronic to take advantage of Ireland's lower business tax rates—12.5 percent versus 35 percent in the United States—in a process known as "tax inversion," the newspaper reported, citing people familiar with the matter.

According to the paper, the talks are well under way, but could still hit snags at the last minute.

A number of US companies, in particular in the , have recently launched bids to buy companies as a way to reduce their costs and tax burden and use their cash overseas.

Pfizer recently abandoned an attempt to buy British firm AstraZeneca for $117 billion in a deal that would have allowed the US company to take advantage of Britain's lower corporate tax rate.

The United States is considering amending its legislation to allow multinational companies to keep overseas indefinitely a portion of their profits in order to avoid paying US taxes on it.

Based in the midwestern US city of Minneapolis, Medtronic makes orthopedic and cardiovascular devices and is valued at around $61 billion, compared to Covidien's $32 billion. Covidien develops devices used in surgery, the Journal said.

Explore further: Google eyeing up to $30 billion in foreign buyouts

Related Stories

Obama promotes influx of foreign investment in US (Update)

May 19, 2014

President Barack Obama held a little-noticed meeting in March with executives of a Belgian aerospace company while in Brussels to meet European leaders. It was barely a footnote in a trip dominated by tensions with Russia ...

AstraZeneca fends off Pfizer with new growth plan

May 6, 2014

AstraZeneca on Tuesday outlined plans to make sales jump over the next decade, an effort to persuade shareholders the drug maker can do well as an independent company, rather than get bought out by rival Pfizer.

Recommended for you

Cryptocurrency rivals snap at Bitcoin's heels

January 14, 2018

Bitcoin may be the most famous cryptocurrency but, despite a dizzying rise, it's not the most lucrative one and far from alone in a universe that counts 1,400 rivals, and counting.

Top takeaways from Consumers Electronics Show

January 13, 2018

The 2018 Consumer Electronics Show, which concluded Friday in Las Vegas, drew some 4,000 exhibitors from dozens of countries and more than 170,000 attendees, showcased some of the latest from the technology world.

Finnish firm detects new Intel security flaw

January 12, 2018

A new security flaw has been found in Intel hardware which could enable hackers to access corporate laptops remotely, Finnish cybersecurity specialist F-Secure said on Friday.

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

BSD
not rated yet Jun 15, 2014
Finance, not science.
ryggesogn2
5 / 5 (1) Jun 16, 2014
Finance, not science.


That's why this story is in the Technology/Business section.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.